What we actually verified
12 GLP-1 telehealth providers — checked against their own pricing and terms pages
State-by-state video requirements — cross-referenced from three major provider state pages
FDA warning letter status — checked on every provider in the matrix against FDA's public warning letter database
Charge timing — confirmed for each pick where possible
Last verified: May 19, 2026 — re-verified quarterly. Where we couldn't confirm a specific data point at the source, we've marked it for you to verify at checkout instead of guessing.
The No-Video-First GLP-1 Provider Matrix (May 2026)
Of 12 U.S. GLP-1 telehealth platforms we verified in May 2026, six default to no-video consultations. Async means a licensed U.S. clinician reviews your file on their own schedule, not live with you. State law and individual medical history can still trigger a video at some providers.
| Provider | Default consult | Video required? | Turnaround | Charge timing | Medication path | Starting price | FDA warning? |
|---|---|---|---|---|---|---|---|
| Eden★ | Async by default in most states | A minority of states (state law) | Often ≤ 24 hours | At checkout | Compounded sema/tirz + brand-name Wegovy, Zepbound, Ozempic, Mounjaro | Compounded sema from $129/mo (3-month plan); brand-name priced separately | None on record |
| Ro★ | Async-style intake; video only for clarification | Provider discretion — not a default scheduled visit | Same-day to 48 hours | At enrollment | FDA-approved only: Foundayo, Wegovy pill/pen, Zepbound pen/KwikPen, Ozempic | $39 first month, then $149/mo or $74/mo (annual); medication separate | None on record |
| SHED★ | Async/non-video; varies by state law and provider group | Only if state law or provider judgment requires | Provider-dependent | At checkout | Compounded sema/tirz including oral & sublingual formats | From $199/mo on oral starter dose | None on record |
| Yucca Health★ | Async medical review; optional post-approval orientation call | Verify in your state at intake | ~24 hours | $0 due today — only charged if Rx is approved | Compounded sema+ and tirz+ (with B12) | Sema from $146/mo (6-month plan); tirz from $258/mo (6-month plan) | None on record |
| Hims / Hers★ | Async-style intake (verify by path and state at checkout) | Variable by path | Same-day | At enrollment | FDA-approved: Wegovy pill, Wegovy pen, Ozempic (via March 2026 Novo Nordisk partnership) | Verify at checkout | None on record |
| Coby Health | Async — "no video unless required by your state" | Only if state law requires | Provider-dependent | At enrollment | GLP-1 telehealth path | Verify at checkout (non-affiliate) | None on record |
| Fridays | Async by default | None routine; not available in Louisiana | Often ~24 hours | At checkout | Compounded sema/tirz | $249/mo (1-mo), $199/mo (3-mo), $175/mo (6-mo), $150/mo (12-mo) | None on record |
| Amble | Async by default | Required in NM, KS, WV, LA, MS | ~24 hours | At checkout | Compounded sema/tirz | $179/mo (1-mo), $160/mo (3-mo), $145/mo (6-mo), $135/mo (12-mo) | None on record |
| Trimi Health | Async questionnaire | None routine | Typically same-day | At enrollment | Compounded sema/tirz | Sema from $99/mo; tirz from $125/mo (verify at checkout) | None on record |
| MEDVi | Async by default | Required in KS, IN, MS, NM, OK, WV; not available in ND | 24–48 hours | After approval | Compounded sema/tirz + branded available | $179/mo first month, then $299/mo | ⚠ FDA warning letter Feb 20, 2026 |
| Bioverse | Online intake with licensed provider review | Verify at intake | Provider-dependent | At enrollment | Compounded path | Verify at checkout | ⚠ FDA warning letter Sept 9, 2025 |
| Bliv | "No phone calls, no video visit" marketing | None claimed | Provider-dependent | At enrollment | Compounded path | Verify at checkout | ⚠ FDA warning letter Feb 20, 2026 |
One page-level damaging admission, said plainly
Most providers on this list dispense compounded GLP-1 medication. Compounded medications are prepared by U.S.-licensed compounding pharmacies and are not FDA-approved as finished drugs — the FDA has not reviewed them for safety, effectiveness, or quality. They may be legally dispensed in some circumstances when prescribed and compounded by properly licensed entities, but they are not in the same regulatory category as brand-name Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo. If FDA-approved status is what you want, use Ro or Hims/Hers.
Is it legal to get a GLP-1 without a video call?
Yes, in general. GLP-1 medications — including semaglutide and tirzepatide — are not controlled substances. The federal in-person exam requirement under the Ryan Haight Act applies to controlled substances and doesn't apply here. The U.S. Department of Health and Human Services explicitly recognizes asynchronous direct-to-consumer telehealth as a legitimate care model on Telehealth.HHS.gov. State law and provider policy still determine whether a written intake alone is enough in your specific state.
A licensed U.S. clinician reviews your medical history and prescribes the medication. The clinician does not have to see you on video.
Some states' medical boards have stricter rules and require a live visit — we list those below.
Any site advertising "no doctor needed" or "no prescription required" is operating outside the law. Avoid them regardless of price.
What "no video call" actually means (and the two async models)
"No video call" means a licensed clinician reviews your medical questionnaire on their own schedule — sometimes called store-and-forward or asynchronous care — and approves your prescription, requests more information, or declines. There are two main flavors:
Model 1: Pure async
You fill out a 5–15 minute intake form. A licensed clinician reviews your file. They approve, request more information through the patient portal, or decline. There is no scheduled phone call. No Zoom. No live chat.
Providers: SHED, Fridays, Trimi, Coby Health, MEDVi (in most states)
Best for: The reader whose primary criterion is zero scheduled live contact.
Model 2: Async with a post-approval orientation call
The medical evaluation itself is still async — no live visit before your prescription is issued. But after you're approved, you're invited to a brief orientation call (typically 15–30 minutes) to walk through your dosing schedule and injection technique.
Providers: Yucca Health is the clearest example.
Best for: The reader who's fine with asynchronous approval but wants one human conversation before they put the first injection in their leg.
Model 3: Hybrid async with video on trigger
Async is the default, but a clinician may request a brief video if your intake raises a question they need to clarify. It's not a scheduled visit — it's a fallback.
Providers: Ro, MEDVi, Amble.
Best for: The reader who's fine with the small chance of a clarification call, especially if it unlocks brand-name or insurance-supported medication (Ro's case).
The 6 best no-video-first GLP-1 providers
Each provider gets a punchline, verified facts, who it's for, and who should skip it. Pricing snapshots taken May 19, 2026 — confirm current promos at checkout.
1. Eden
The punchline: Eden is the strongest broad pick for most readers. Async by default in most states, both compounded and brand-name medications available on the same platform, free intake that doesn't charge until you check out, and same-price-at-every-dose structure that prevents the hidden cost creep most programs hit you with at month 3.
What we verified
Consultation method: Async-default. In most states, you communicate with your provider asynchronously through the secure portal. Some states require a video visit by state law.
States with compounded restrictions: Arkansas, Louisiana, Mississippi, and New Mexico for certain compounded formulations. Verify your state at intake.
Medications: Compounded semaglutide and tirzepatide. Brand-name Wegovy, Zepbound, Ozempic, Mounjaro available.
Pricing: Compounded semaglutide starts at $129 first month on a 3-month plan. Brand-name medications carry separate, higher pricing. Eden states pricing stays the same across dose levels, with the caveat that promotional periods may not follow that rule.
Charge timing: At checkout — not upfront.
Best for
- ✅ Broadest async default in most states
- ✅ Compounded + brand-name on one platform
- ✅ Free intake before billing
- ✅ Same price at every dose level
Skip Eden if
- → You want insurance to cover your medication (Ro)
- → You live in AR, LA, MS, or NM (check at intake)
- → You need a 3-month minimum commitment workaround
2. Ro
The punchline: If you specifically want FDA-approved brand-name medication (Wegovy, Zepbound, Foundayo) and you don't want a scheduled video, Ro is the path. Async-style intake with video only if the clinician needs clarification — not a default scheduled visit. Dedicated insurance concierge fights prior authorization on your behalf.
What we verified
Consultation method: Async intake; provider may request a brief video for clarification only — not a default scheduled visit.
Medications: FDA-approved only: Foundayo (orforglipron), Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, and Ozempic (off-label for weight when clinically appropriate).
Insurance support: Dedicated insurance concierge that files your prior authorization. Free GLP-1 Insurance Coverage Checker available before enrollment.
Membership pricing: $39 for the first month, then $149/month ongoing or as low as $74/month with annual plan paid upfront. Medication cost priced separately.
Damaging admission
Ro is not the cheapest provider on this list — compounded providers like Eden, SHED, and Yucca start under $200 a month on the medication itself. If price is your only filter and you're comfortable with compounded medication, choose one of those instead. But for FDA-approved brand-name medication + insurance support + no scheduled video, Ro is the strongest verified combination.
Best for
- ✅ FDA-approved (not compounded) medication
- ✅ Insurance users — Ro files the prior auth
- ✅ Wegovy, Zepbound, or Foundayo seekers
- ✅ Lowest regulatory risk profile
Skip Ro if
- → You only want compounded at lowest price (Eden or Yucca)
- → You live in HI, LA, MS, or VA (Ro Body not available)
- → You're on Medicare/Medicaid (Ro doesn't coordinate government plans)
- → You want a scheduled live video
3. SHED
The punchline: SHED is the strongest async-first pick if needles are a dealbreaker. Compounded oral and sublingual GLP-1 formulations, async-first communication, and explicit terms-of-service language about non-video evaluation.
What we verified
Consultation method: SHED's terms state that asynchronous/non-video medical evaluation availability varies by state law and provider group. In practice, communication is text/email-based for most patients.
Medications: Compounded semaglutide and tirzepatide in injectable, oral, and sublingual lozenge formats. Brand-name Wegovy and Zepbound also listed.
Pricing: From $199/mo at the starter dose for compounded oral semaglutide; titrates up to ~$299/mo at higher doses.
Minimum commitment: 2 months. Cancellation must be made 72+ hours before the next billing cycle.
LegitScript certified: Yes.
Damaging admission
SHED's support model is asynchronous email/text only — no real-time chat, no phone hotline. Some patients report longer response times during high-demand periods. If high-touch live support is a must, Eden or Yucca may fit better.
Best for
- ✅ Needle-averse adults
- ✅ Oral or sublingual semaglutide explorers
- ✅ Readers who actively want zero scheduled live interaction
Skip SHED if
- → You want frequent live provider access
- → You need a 1-month trial with no commitment
4. Yucca Health
The punchline: Yucca Health is the cleanest "$0 until approved" model we verified, and it earns 4.6/5 across more than 1,000 public reviews on Trustpilot specifically because the model is so smooth for readers who fit clean GLP-1 eligibility criteria.
What we verified
Consultation method: Async medical review. Per Yucca's own semaglutide page: "Licensed providers review your intake asynchronously — meaning no live doctor visit is required. If needed, they may follow up through the secure patient portal."
Charge timing: $0 due at intake. Card only billed if your prescription is approved.
Medications: Compounded Semaglutide+ and Tirzepatide+ (with B12 vitamin boost included in the formulation).
Decision turnaround: ~24 hours per Yucca's published material.
Pricing: Semaglutide from $146/mo (6-month plan); tirzepatide from $258/mo (6-month plan). Month-to-month runs higher.
Shipping: UPS 2-Day Air included in every plan.
Trustpilot: 4.6 out of 5 from over 1,000 reviews as of May 2026.
"I have just started my Yucca Health journey and I have been extremely impressed with the ease of their portal. I am also appreciative of their prompt responses answering any of my questions."
— Trustpilot verified review
Best for
- ✅ Cost-conscious readers who refuse to pay before approval
- ✅ Async evaluation + optional post-approval human touchpoint
- ✅ 6-month plan committers (best per-month pricing)
Skip Yucca if
- → You want brand-name FDA-approved medication (go to Ro)
- → You want to chat with a clinician live before being prescribed
5. Hims (men) / Hers (women)
The punchline: After Hims & Hers announced a partnership with Novo Nordisk in March 2026, both platforms now offer access to FDA-approved Wegovy pill, Wegovy pen, and Ozempic. The intake is online and async-style for most paths — the FDA-approved status is the real thing.
What we verified
Medications: FDA-approved Wegovy pill, Wegovy pen, and Ozempic (all Novo Nordisk products) via the March 2026 partnership.
Consultation method: Async-style intake for most paths; verify the specific flow for your state at checkout.
Membership note: Hims/Hers' announcement confirms membership doesn't guarantee a prescription and medication is not available without membership.
Pricing: Verify current pricing at checkout — Hims/Hers structures vary across plans.
Best for
- ✅ Readers who recognize and trust the Hims or Hers brand
- ✅ FDA-approved brand-name medication + familiar app experience
Skip Hims/Hers if
- → You want the lowest monthly cost on compounded (Eden or Yucca)
- → You want an insurance concierge filing prior authorizations (Ro)
6. Coby Health
We don't earn anything from including Coby Health. It's here because it answers your question with the cleanest possible language, and a trust-first comparison page should name the best exact-fit answers regardless of whether they pay us.
What we verified: Coby Health publicly states no video visit is required unless your state requires one. Provider reviews your intake online.
Before you sign up, verify
- 1. Current pricing on their pricing page
- 2. They ship to your state
- 3. Which pharmacy fulfills your prescription
- 4. Whether the medication is compounded or FDA-approved
One more group we need to address: MEDVi, Bliv, and Bioverse
We're not going to bury this. All three are large platforms. All three have exact-match no-video positioning. None of the three are in our top picks for a 2026 trust-first guide.
⚠ MEDVi
FDA issued a public warning letter dated February 20, 2026 about misleading marketing claims for compounded GLP-1 products on its website.
⚠ Bliv Wellness LLC
FDA issued a public warning letter dated February 20, 2026 for similar marketing issues. Bliv markets itself explicitly as "no phone calls, no video visit."
⚠ Bioverse Medical LLC
FDA issued a public warning letter dated September 9, 2025 for claims that compounded products are the "same active ingredient" as Ozempic, Wegovy, Mounjaro, and Zepbound — which the FDA called false and misleading.
These are real regulatory enforcement actions. They are not recalls, not shutdowns, and not findings against the medical programs or pharmacy partners. They are formal regulatory objections to specific marketing language used to describe compounded medication.
We're naming all three, telling you what happened, and routing you toward Eden, Ro, or Yucca first. If you've already used one of these platforms and had a good experience, none of this is meant to override your judgment. But if you're choosing for the first time in May 2026, we'd point you elsewhere until corrective action is publicly verifiable.
State and provider video requirements we found
This is a provider-policy table, not a complete state-telehealth-law table. It shows where major no-video-first providers publicly say a live audio or video step may still be required. State requirements change — confirm with your provider at intake before paying.
| State | Providers that require a live visit here | Compounded availability restriction |
|---|---|---|
| Kansas | MEDVi, Amble | — |
| Indiana | MEDVi | — |
| Mississippi | MEDVi, Amble | Eden — certain compounded formulations |
| New Mexico | MEDVi, Amble | Eden — certain compounded formulations |
| Oklahoma | MEDVi | — |
| West Virginia | MEDVi, Amble | — |
| Louisiana | Amble | Fridays (does not ship to LA); Eden — certain compounded formulations |
| Arkansas | — | Eden — certain compounded formulations |
| North Dakota | — | MEDVi not available |
Yucca Health, Coby Health, and SHED do not appear on this list of provider-stated state video overrides as of May 2026, but state requirements change — verify at intake in your state before paying.
Not sure which state you're in, or want a personalized pick?
Compare Eden, Ro, SHED, and Yucca side by side — or take the 60-second quiz for a recommendation built for your state, budget, and goals.
6-point pre-purchase checklist for any async GLP-1 provider
| What to confirm | Why it matters | Where to find it |
|---|---|---|
| Named pharmacy partner | You need to know where your medication comes from | Provider website footer or FAQ |
| State availability is confirmed | Some providers don't ship to your state | Checkout or state availability page |
| Total monthly cost after the promo | Intro pricing often steps up at month 2 or 3 | Pricing terms / FAQ |
| Higher-dose pricing | Some providers raise the price when your dose escalates | Pricing terms |
| Cancellation timing | Most async providers need 72-hour cancellation notice | Terms of service / cancellation policy |
| Side-effect support | You need a way to reach a clinician between visits | Patient portal / support page |
| LegitScript certification or equivalent | Independent compliance check | LegitScript.com or the provider's footer |
If a provider can't pass this checklist in 60 seconds of clicking around their own site, don't pay them. Pay someone else.
Red flags: when "no video call" becomes "no real medical care"
Convenience and carelessness are not the same thing. Five red flags that turn legitimate async telehealth into something dangerous:
Red flag 1: No prescription required
No legitimate U.S. provider can sell you a GLP-1 medication without a prescription from a licensed clinician. If you see "no prescription needed," walk away. This is the FDA's explicit guidance — they've warned consumers about this through 2025 and 2026.
Red flag 2: Compounded medication marketed like FDA-approved medication
Phrases to watch for: "the same as Ozempic," "FDA-approved compounded semaglutide," "generic Wegovy," "the same active ingredient as Mounjaro." Compounded medications are not FDA-approved finished drugs. The FDA issued 50+ warning letters in September 2025 and 30 more in March 2026 for exactly this pattern.
Red flag 3: No pharmacy disclosure
A legitimate provider names its compounding pharmacy partner. MEDVi names Belmar Pharma Solutions. Eden states medications are dispensed by state-licensed pharmacies. If a provider won't tell you which pharmacy is filling your prescription, you don't know where your medication is coming from.
Red flag 4: Guaranteed approval
You should be able to be declined by a legitimate provider. If a site's language strongly implies 'everyone gets approved,' the clinical review may be more performative than real. Yucca Health explicitly notes that not everyone qualifies and your card isn't charged unless you're approved. That's the right model.
Red flag 5: Promo pricing without a clear post-promo cost
A $99 first-month price that becomes $299/month after the promo isn't necessarily wrong — but it has to be visible before you pay. If you have to click through three layers to find what month 2 costs, the provider is hoping you'll forget.
Honest downsides of no-video GLP-1 care
Async-first GLP-1 care has real tradeoffs. For many readers with straightforward histories, these are acceptable. For readers with complex medical histories, they're not.
No live read of you as a person
A clinician can't read tone or hesitation through a questionnaire. If your situation is nuanced — history of disordered eating, complex drug interactions, GI conditions — they're working from your written answers.
Slower clarification loops
If the clinician needs to ask a follow-up, it goes through the patient portal. That loop can add days.
Total dependence on you to answer honestly
Async only works if your intake is accurate. Skipping or downplaying a contraindication (medullary thyroid cancer history, MEN-2, pancreatitis, pregnancy) is dangerous.
No "the doctor seemed fine with my situation" reassurance
Some readers genuinely benefit from a 5-minute live conversation. It's a real difference.
Who should not use async-only GLP-1 care
Async-only is not the right path for everyone. If one row applies to you, please don't proceed with the async path on our recommendation.
| If this is you | Why this needs higher-touch clinical review | Where to go instead |
|---|---|---|
| Pregnant, breastfeeding, or trying to conceive | GLP-1s carry contraindications and warnings in pregnancy per FDA labeling. | Speak with your OB/GYN. |
| Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 | This is a boxed-warning contraindication on GLP-1 labels. | An endocrinologist, not a telehealth platform. |
| History of pancreatitis or severe gastroparesis | A live evaluation matters here. | A video-included provider |
| Severe renal impairment | Careful dosing required. | Video-included provider |
| Currently using insulin or sulfonylureas | Hypoglycemia risk is meaningfully higher. | Video-included provider |
| Complex multi-medication regimen | Drug interaction review is better live. | Video-included provider |
| Under 18 | Most platforms restrict to adults. | Pediatric obesity specialist. |
If one of these applies to you, compare video-included GLP-1 providers instead.
See Video-Included Providers →Compounded vs. FDA-approved — the one paragraph version
Compounded GLP-1 medications and FDA-approved brand-name GLP-1 medications are not the same regulatory category and should not be marketed as if they were. FDA-approved Wegovy, Wegovy pill, and Ozempic are Novo Nordisk products; Zepbound, Mounjaro, and Foundayo are Eli Lilly products — all manufactured under FDA oversight and studied in controlled clinical trials. Compounded semaglutide and tirzepatide are prepared by U.S.-licensed compounding pharmacies. They are not FDA-approved finished drugs, and the FDA has stated it has not reviewed them for safety, effectiveness, or quality. We're not going to say compounded is bad. But we are going to be clear: compounded medications are different from FDA-approved brand-name drugs. If FDA-approved status is what you want, go to Ro for brand-name access.
Frequently asked questions
How we built this guide
We're an independent comparison resource for GLP-1 telehealth providers. Here's what we checked, provider by provider:
Public pricing and terms pages — pricing and consultation-method claims come from the providers' own published pages
State availability lists where published
Pharmacy partner disclosures (named or not)
LegitScript certification status where applicable
FDA warning letter history — checked against the FDA's public warning letter database
Public review aggregates on Trustpilot, ConsumerAffairs, and BBB for service/experience signals only — not for medical efficacy claims
Three FDA warning letters worth knowing about
- • Bioverse Medical LLC — warning letter dated September 9, 2025, regarding "same active ingredient" marketing for compounded semaglutide and tirzepatide.
- • MEDVi, LLC — warning letter dated February 20, 2026, regarding compounded GLP-1 marketing claims.
- • Bliv Wellness LLC — warning letter dated February 20, 2026, regarding compounded GLP-1 marketing claims.
How often we re-verify: Pricing quarterly + ad-hoc. Consultation method and state overrides: quarterly. FDA warning letter status: monthly during the current enforcement wave. The "Last verified" date at the top is the single source of truth.
Still not sure which one fits you?
The right pick depends on your state, your budget, whether you care about FDA-approved status, and whether you're open to compounded medication. Our free 60-second quiz gives you a personalized recommendation built for your situation.
Take the Free 60-Second GLP-1 Quiz →About this guide
Who created it: The WPG Research Team — an independent comparison resource for GLP-1 telehealth providers.
Our affiliate position, said clearly: We earn a commission when readers sign up through some of our links. We don't earn from Coby Health. We include providers whether or not we have an affiliate relationship when the evidence supports including them. We don't accept payment for ranking placement. Our full disclosure is here.
Medical disclaimer: We don't claim to be a medical authority and we don't put a fake clinical reviewer's name on this page. This is editorial research and comparison — not medical advice. Always consult a licensed clinician before starting any new medication.